ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 164 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2016. The put-call ratio across all filers is 1.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $5,994,517 | -12.0% | 145,852 | 0.0% | 0.00% | -20.0% |
| Q1 2024 | $6,809,830 | +0.6% | 145,852 | +3.0% | 0.01% | 0.0% |
| Q4 2023 | $6,769,017 | +22.0% | 141,552 | -9.1% | 0.01% | +25.0% |
| Q3 2023 | $5,548,994 | -21.3% | 155,652 | +1.8% | 0.00% | -20.0% |
| Q2 2023 | $7,051,063 | +22.3% | 152,852 | +6.3% | 0.01% | +25.0% |
| Q1 2023 | $5,764,455 | -22.6% | 143,752 | -10.5% | 0.00% | -20.0% |
| Q4 2022 | $7,443,007 | +14.1% | 160,652 | +2.0% | 0.01% | 0.0% |
| Q3 2022 | $6,524,000 | -29.6% | 157,552 | +1.5% | 0.01% | -16.7% |
| Q2 2022 | $9,262,000 | -16.7% | 155,252 | +1.4% | 0.01% | 0.0% |
| Q1 2022 | $11,122,000 | -6.8% | 153,152 | +8.0% | 0.01% | -14.3% |
| Q4 2021 | $11,928,000 | -6.6% | 141,852 | +0.1% | 0.01% | -12.5% |
| Q3 2021 | $12,776,000 | -4.4% | 141,652 | +1.1% | 0.01% | 0.0% |
| Q2 2021 | $13,363,000 | -18.2% | 140,152 | -2.4% | 0.01% | -27.3% |
| Q1 2021 | $16,345,000 | -9.3% | 143,552 | +10.3% | 0.01% | -15.4% |
| Q4 2020 | $18,017,000 | +70.4% | 130,152 | +1.2% | 0.01% | +62.5% |
| Q3 2020 | $10,574,000 | +10.1% | 128,652 | +4.8% | 0.01% | 0.0% |
| Q2 2020 | $9,602,000 | +103.0% | 122,752 | +15.3% | 0.01% | +60.0% |
| Q1 2020 | $4,730,000 | +5.6% | 106,452 | +1.5% | 0.01% | 0.0% |
| Q4 2019 | $4,478,000 | +1.8% | 104,852 | +1.9% | 0.01% | 0.0% |
| Q3 2019 | $4,400,000 | -30.5% | 102,852 | +3.2% | 0.01% | -28.6% |
| Q2 2019 | $6,328,000 | -7.1% | 99,652 | +1.4% | 0.01% | 0.0% |
| Q1 2019 | $6,815,000 | +86.0% | 98,252 | +16.6% | 0.01% | +40.0% |
| Q4 2018 | $3,663,000 | -41.5% | 84,252 | +2.7% | 0.01% | -28.6% |
| Q3 2018 | $6,264,000 | -0.7% | 82,052 | 0.0% | 0.01% | 0.0% |
| Q2 2018 | $6,307,000 | +59.3% | 82,052 | +5.7% | 0.01% | +40.0% |
| Q1 2018 | $3,959,000 | +22.0% | 77,652 | +11.0% | 0.01% | +25.0% |
| Q4 2017 | $3,244,000 | -9.4% | 69,952 | +4.0% | 0.00% | 0.0% |
| Q3 2017 | $3,582,000 | -12.7% | 67,252 | +1.8% | 0.00% | -20.0% |
| Q2 2017 | $4,102,000 | -5.4% | 66,052 | +3.3% | 0.01% | 0.0% |
| Q1 2017 | $4,335,000 | +0.2% | 63,952 | +3.9% | 0.01% | -28.6% |
| Q4 2016 | $4,328,000 | +1.6% | 61,552 | +2.5% | 0.01% | 0.0% |
| Q3 2016 | $4,260,000 | +44.3% | 60,052 | -0.5% | 0.01% | +40.0% |
| Q2 2016 | $2,952,000 | +9.2% | 60,352 | +36.3% | 0.01% | 0.0% |
| Q1 2016 | $2,704,000 | -31.8% | 44,267 | +25.2% | 0.01% | -50.0% |
| Q4 2015 | $3,967,000 | +18.1% | 35,367 | +1.4% | 0.01% | +11.1% |
| Q3 2015 | $3,358,000 | +29.1% | 34,867 | +37.3% | 0.01% | +28.6% |
| Q2 2015 | $2,601,000 | +64.9% | 25,400 | 0.0% | 0.01% | +75.0% |
| Q1 2015 | $1,577,000 | +87.3% | 25,400 | +32.3% | 0.00% | +33.3% |
| Q4 2014 | $842,000 | +135.9% | 19,200 | +204.8% | 0.00% | +200.0% |
| Q3 2014 | $357,000 | +26.1% | 6,300 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $283,000 | – | 6,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 217,459 | $24,760,000 | 1.64% |
| Motley Fool Asset Management LLC | 152,326 | $17,344,000 | 1.25% |
| Rock Springs Capital Management LP | 450,000 | $51,237,000 | 1.12% |
| AtonRa Partners | 21,017 | $2,393,000 | 1.07% |
| SECTORAL ASSET MANAGEMENT INC | 112,200 | $12,775,000 | 0.97% |
| EMERALD ADVISERS, LLC | 228,368 | $26,002,000 | 0.94% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 239,023 | $27,215,000 | 0.90% |
| FEDERATED HERMES, INC. | 3,912,408 | $445,467,000 | 0.86% |
| HealthCor Management, L.P. | 207,610 | $23,638,000 | 0.84% |
| Atika Capital Management LLC | 66,000 | $7,515,000 | 0.65% |